Skip to main content
Ingenium Logo

You are leaving IngeniumCanada.org

✖


This link leads to an external website that Ingenium does not control. Please read the third-party’s privacy policies before entering personal information or conducting a transaction on their site.

Have questions? Review our Privacy Statement

Vous quittez IngeniumCanada.org

✖


Ce lien mène à un site Web externe qu'Ingenium ne contrôle pas. Veuillez lire les politiques de confidentialité des tiers avant de partager des renseignements personnels ou d'effectuer une transaction sur leur site.

Questions? Consultez notre Énoncé de confidentialité

Ingenium The Channel

Langue

  • Français
Search Toggle

Menu des liens rapides

  • Ingenium Locations
  • Shop
  • Donate
  • Join
Menu

Main Navigation

  • Browse
    • Categories
    • Media Types
    • Boards
    • Featured Stories
  • About
    • About The Channel
    • Content Partners

Immunity against disease

This article was originally written and submitted as part of a Canada 150 Project, the Innovation Storybook, to crowdsource stories of Canadian innovation with partners across Canada. The content has since been migrated to Ingenium’s Channel, a digital hub featuring curated content related to science, technology and innovation.

Share
Jun 29, 2017
Categories
Medicine
Media
Article
Profile picture for user Centre for the Commercialization of Antibodies and Biologics
By: Centre for the Commercialization of Antibodies and Biologics
Immune system

Our body’s immune system is by and large a smooth-running operation. This complex system of organs, tissues and specialized cells destroys foreign invaders and rids the body of damaged and diseased cells. However, there are times when infections or diseases evade this protective process; one example is cancer.

In some cases, it’s possible to give the immune system a boost. Scientists have been exploring ways to do this, and over the past several years, they have successfully developed drugs that stimulate the immune system to treat diseases like cancer.

How are these therapies developed?

Many of these immune-boosting therapies are synthetic antibodies. While naturally-occurring, antibodies are the fighter molecules of the immune system, scientists can now engineer synthetic antibodies in the laboratory to match specific disease targets. Antibody therapeutics, which are part of a class of protein-based drugs called biologics, have emerged as the fastest growing segment of the pharmaceutical industry. In fact, Canada originated the biologics revolution with the discovery of insulin in 1921.

In Toronto, the Centre for the Commercialization of Antibodies and Biologics (CCAB) is focused on developing biologics and helping to translate them into validated therapies. Working closely with the Toronto Recombinant Antibody Centre (TRAC), the University of Toronto’s antibody discovery engine, CCAB bridges research and discovery at TRAC to commercial development, playing an important role in moving therapies from the laboratory to patients.

TRAC represents a unique model of scientific collaboration. It brings together scientists and clinicians who have a broad range of interests and expertise. Using state-of-the-art technology, this highly-skilled multidisciplinary team has produced thousands of high-quality antibodies against numerous disease targets, including cancers, diabetes, obesity and infectious diseases. These antibodies are designed such that they can be immediately evaluated for potential as new therapies.

The partnership between CCAB and TRAC represents an essential connection along Canada’s drug development pipeline. While our country’s scientists are recognized as being at the forefront of basic biological research, there has been a gap between the outstanding academic research undertaken in Canadian laboratories and its translation into concrete benefits for patients and the economy. CCAB helps to fill this gap by mediating and strengthening the connections between academia and industry.

Collaborating for better therapies

CCAB was established in 2014 by Dr. Sachdev Sidhu, a professor at the University of Toronto. He is now CCAB’s chief scientific officer. Dr. Sidhu also led the creation of TRAC in 2010 and has been recognized for his significant contributions to advancing protein science technology. Dr. Sidhu and his colleagues at the University of Toronto have developed new methods allowing the quick and efficient production of synthetic antibodies that are optimized for therapeutic use and have exquisite specificity for their intended target.

Currently, CCAB has an extensive portfolio of antibodies – 1,000 validated leads against more than 200 targets associated with cancer, inflammation, and autoimmune and infectious diseases. By building antibodies with drug development in mind, CCAB aims to move promising drugs to market more quickly by facilitating their transfer to industry.

Working with partners throughout North America, CCAB is looking to accelerate the development of treatments for some of the most challenging cancers – brain (glioblastoma), pancreatic and ovarian. Collaborating with international partners in China and India, CCAB is also working on developing therapies for infectious diseases such as dengue fever and MERS (Middle East Respiratory Syndrome).

Keeping pace with growing biotech innovation: our vision for the future

Neither science nor business stand still, Dr. Sidhu says, and CCAB is continually integrating new innovations in biologics stemming from academic research.

For example, engineered antibodies are constantly evolving with the introduction of new formats with improved potential for development into new therapies. These are first designed in research laboratories at the University of Toronto and then implemented into the TRAC pipeline.

Likewise, while antibodies are one class of proteins that has been used as a template for developing synthetic therapeutics, engineered versions of other proteins are currently being explored, including synthetic variants of ubiquitin and erythropoietin. CCAB plans to apply their established R&D and business model to bring some of these promising new drugs to market for the benefit of patients.

CCAB’s vision is to be instrumental in the creation of a new biotech eco-system in Canada by expanding partnerships with existing industry and promoting the creation of start-up companies to commercialize Canadian-developed innovative biologics.

“It’s an exciting time for CCAB,” Dr. Sidhu says, “and, more importantly, it’s an exciting time for the scientific opportunities to develop treatments for some of the most challenging diseases.”

Transcript

The Centre for the Commercialization of Antibodies and Biologics (CCAB) translates early stage biologics into high-value assets and products. Our Partners can access a robust portfolio of validated antibodies and biologics, powered by the University of Toronto's antibody research and discovery engine: the Toronto Recombinant Antibody Centre (TRAC). Work with us to access world-class expertise, a state-of-the-art phage display discovery platform, established antibody libraries and validated screening technologies.

Tags
Innovation Storybook
Author(s)
Profile picture for user Centre for the Commercialization of Antibodies and Biologics
Centre for the Commercialization of Antibodies and Biologics

The Centre for the Commercialization of Antibodies and Biologics (CCAB) provides expertise in product and business development to rapidly translate academic discoveries toward achieving a sustainable impact within the healthcare system and the broader scientific research community.

https://ccabcanada.com

Related Stories

A large impact crater viewed from the rim, a woodern spoon full of small yellow grains, a close up of a forearm being tattooed.

3 things you should know about the untapped potential of millet, the permanence of tattoos, and asteroid airbursts

The 3.75- / 3.5-inch flight impact simulator of the National Research Council of Canada at some point during its long career, Uplands / Ottawa, Ontario. NRC.

A great Canadian success story you should know about: A brief look at the National Research Council of Canada flight impact simulators donated to the Canada Aviation and Space Museum, Part 2

Three images side by side: A little girl smells a sunflower, the DART spacecraft’s impact into the asteroid Dimorphos, and a candy apple

3 things you should know about how the DART spacecraft changed the orbit of an asteroid, how we have more than five senses, and how the science of caramel can make you a better cook!

Three images side by side, plastic-wrapped cucumbers, a woman with an inflamed shoulder, and the James Webb Space Telescope.

3 things you should know about plastic-wrapped cucumbers, the James Webb telescope, and inflammation

A small, open box containing several small metal puncturing tools, used to administer smallpox vaccine by scratching the skin and rubbing the vaccine into the scratch.

The History of Vaccines – Smallpox to COVID-19

Stethoscopes displayed in the permanent Medical Sensations exhibition at the Canada Science and Technology Museum.

Curating sound culture: Exploring the history of the stethoscope

A close-up view of a radio pill a few moments before the first volunteer patient swallowed it. Anon., “Science – Radio Made to Swallow.” Life, 29 April 1957, 74.

Take one of these pills and your innards will call me in the morning: The digestive saga of… the radio pill

A text-based advertisement for Speton.

McGill-Ingenium Fellowship: Part Two - A Tale of Two Nations: Birth Control in India and Canada (1930–60s)

Autumn vista of a river winding between pine trees and snow-capped mountains.

AI-Generated sound therapy for critically ill patients

Aticle from an issue of Guna Sundari in 1936.

McGill-Ingenium Fellowship: Part One - A Historian & Her Archives

A spliced, three-part image depicts sugar beets and a pile of white sugar and sugar cubes, a view of a partially cloud-covered ocean taken from above the Earth, and a humanoid toy robot wearing a stethoscope.

3 things you should know about beets, satellites, and robotic surgery

A pancreas made of light floats between the hands of a woman wearing a white lab coat, a mask, and a stethoscope.

Innovation and the future of diabetes: A conversation with an entrepreneur and diabetes dad

Footer

About The Channel

The Channel

Contact Us

Ingenium
P.O. Box 9724, Station T
Ottawa ON K1G 5A3
Canada

613-991-3044
1-866-442-4416
contact@IngeniumCanada.org
  • Facebook
  • Instagram
  • Twitter
  • Channel

    • Channel Home
    • About the Channel
    • Content Partners
  • Visit

    • Online Resources for Science at Home
    • Canada Agriculture and Food Museum
    • Canada Aviation and Space Museum
    • Canada Science and Technology Museum
    • Ingenium Centre
  • Ingenium

    • Ingenium Home
    • About Ingenium
    • The Foundation
  • For Media

    • Newsroom
    • Awards

Connect with us

Subscribe to our newsletter to receive the latest Ingenium news straight to your inbox!

Sign Up

Legal Bits

Ingenium Privacy Statement

© 2023 Ingenium

Symbol of the Government of Canada
  • Browse
    • Categories
    • Media Types
    • Boards
    • Featured Stories
  • About
    • About The Channel
    • Content Partners